10 Recruiting Waldenstrom Macroglobulinemia Phase 2 Clinical Trials
Active phase 2 studies for waldenstrom macroglobulinemia enrolling across the USA. Verify eligibility and contact site coordinators.
All Waldenstrom Macroglobulinemia studiesPhase 2 Studies for Waldenstrom Macroglobulinemia
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
π Cellectar Biosciences site β Los Angeles, California
View Study & Checklist βPirtobrutinib and Venetoclax in WaldenstrΓΆm Macroglobulinemia
π Beth Israel Deaconness Medical β Boston, Massachusetts
View Study & Checklist βA Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With WaldenstrΓΆm Macroglobulinemia
π City of Hope National Medical Center β Duarte, California
View Study & Checklist βBendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia
π Tom Baker Cancer Centre β Calgary, Alberta
View Study & Checklist βIbrutinib + Venetoclax in Untreated WM
π Massachusetts General Hospital β Boston, Massachusetts
View Study & Checklist βLoncastuximab Tesirine in WM
π Dana Farber Cancer Institute β Boston, Massachusetts
View Study & Checklist βMosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER)
π Huntsman Cancer Institute at University of Utah β Salt Lake City, Utah
View Study & Checklist βEpcoritamab in Previously Treated WM
π Beth Israel Deaconess Medical Center β Boston, Massachusetts
View Study & Checklist βZanubrutinib, Bendamustine, Rituximab Prev. Untreated WM
π Colorado Blood Cancer Institute (CBCI) β Denver, Colorado
View Study & Checklist βA Study of Pirtobrutinib, Venetoclax, and Rituximab in People With WaldenstrΓΆm's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
π Dana Farber Cancer Institute (Data Collection and Specimen Analysis) β Boston, Massachusetts
View Study & Checklist β